Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease
Buciuc, Marina , Josephs, Keith A. , Jones, David T. , Whitwell, Jennifer L. , Graff‐Radford, Jonathan , Josephs, Keith A , Buciuc, Marina , Jones, David T , Whitwell, Jennifer L , Graff-Radford, Jonathan

Mayo Clinic

Neurology | September 10, 2021 | Volume: 97 | Issue: 19 | Pages: 908-909

10.1212/wnl.0000000000012783 | PMID 34504027 Get It

Pain Catastrophizing and Pain Self-Efficacy Mediate Interdisciplinary Pain Rehabilitation Program Outcomes at Posttreatment and Follow-Up
Schumann, Matthew E. , Gascho, Keith , Geske, Jennifer R. , McDermott, Mary C., Reynolds, Andrea L, Bernau, Jessica L, Gilliam, Wesley P. , Gascho, Keith E, Morrison, Eleshia J, Schumann, Matthew , Geske, Jennifer , Coombes, Brandon J. , Morrison, Eleshia J. P.

Mayo Clinic

Pain Medicine | September 9, 2021 | Volume: 23 | Issue: 4 | Pages: 697-706

10.1093/pm/pnab271 | PMID 34519826 Get It

Abstract Background Decreasing pain catastrophizing and improving self-efficacy to self-manage chronic pain symptoms are important treatment targets in the context of interdisciplinary pain rehabilitation. Greater pain catastrophizing has been shown to be associated with greater impact of pain symptoms on functioning; conversely, greater pain self-efficacy has been associated with lower pain intensity and lower levels of disability. Objective To prospectively evaluate interdisciplinary pain rehabilitation outcomes, as well as to evaluate the mediating effects of both pain catastrophizing and pain self-efficacy on outcome. Methods Participants were 315 patients with chronic pain between April 2017 and April 2018 who completed a 3-week interdisciplinary pain rehabilitation program. Pain severity, pain interference, pain catastrophizing, pain self-efficacy, quality of life, depressive symptom questionnaires, and measures of physical performance were assessed before and after treatment. Follow-up questionnaires were returned by 163 participants. Effect size and reliable change analyses were conducted from pre- to posttreatment and from pretreatment to 6-month follow-up. Mediation analyses were conducted to determine the mediating effect of pain catastrophizing and pain self-efficacy on pain outcome. Results Significant improvements from pre- to posttreatment in pain outcomes were observed, and more than 80% evidenced a reliable change in at least one pain-relevant measure. Pain catastrophizing and pain self-efficacy mediated the relationship between changes in pain outcomes. Conclusions Interdisciplinary pain rehabilitation is an effective treatment, and decreasing pain catastrophizing and increasing pain self-efficacy can influence maintenance of treatment gains.
Receptivity to a Nurse-Led Symptom Management Intervention Among Highly Symptomatic Patients With Cancer
Wintheiser, Grant , Ruddy, Kathryn J. , Herrin, Jeph , Rahman, Parvez, Pachman, Deirdre R. , Leppin, Aaron L. , Lee, Minji K. , Tofthagen, Cindy , Wintheiser, Grant A , Rahman, Parvez A, Lee, Minji K , Tofthagen, Cindy S , Chlan, Linda L , Ridgeway, Jennifer L , Mitchell, Sandra A , Herrin, Jeph , Rutten, Lila J. Finney , Griffin, Joan M. , Chlan, Linda L. , Ridgeway, Jennifer L. , Cheville, Andrea

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 9, 2021 | Volume: 114 | Issue: 3 | Pages: 458-466

10.1093/jnci/djab172 | PMID 34508602 Get It

Abstract Background The symptom burden associated with cancer and its treatment can negatively affect patients’ quality of life and survival. Symptom-focused collaborative care model (CCM) interventions can improve outcomes, but only if patients engage with them. We assessed the receptivity of severely symptomatic oncology patients to a remote nurse-led CCM intervention. Methods In a pragmatic, cluster-randomized, stepped-wedge trial conducted as part of the National Cancer Institute IMPACT Consortium (E2C2, NCT03892967), patients receiving cancer care were asked to rate their sleep disturbance, pain, anxiety, emotional distress, fatigue, and limitations in physical function. Patients reporting at least 1 severe symptom (≥7/10) were offered phone consultation with a nurse symptom care manager (RN SCM). Initially, patients had to “opt-in” to receive a call, but the protocol was later modified so they had to “opt-out” if they did not want a call. We assessed the impact of opt-in vs opt-out framing and patient characteristics on receptiveness to RN SCM calls. All statistical tests were 2-sided. Results Of the 1204 symptom assessments (from 864 patients) on which at least 1 severe symptom was documented, 469 (39.0%) indicated receptivity to an RN SCM phone call. The opt-out period (odds ratio [OR] = 1.61, 95% confidence interval [CI] = 1.12 to 2.32, P = .01), receiving care at a tertiary care center (OR = 3.59, 95% CI = 2.18 to 5.91, P < .001), and having severe pain (OR = 1.80, 95% CI = 1.24 to 2.62, P = .002) were associated with statistically significantly greater willingness to receive a call. Conclusions Many severely symptomatic patients were not receptive to an RN SCM phone call. Better understanding of reasons for refusal and strategies for improving patient receptivity are needed.
Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: An Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document
Greninger, Alexander L. , Bard, Jennifer Dien , Colgrove, Robert C. , Hayden, Mary K. , Humphries, Romney M. , Lowe, Christopher F. , Pillai, Dylan R. , Rhoads, Daniel D. , Yao, Joseph D. , Lee, Francesca M, Graf, Erin H. , Humphries, Romney , Rhoads, Daniel D , Greninger, Alexander L , Hanson, Kimberly E. , Miller, Melissa B.

Mayo Clinic

Clinical Infectious Diseases | September 8, 2021 | Volume: 74 | Issue: 8 | Pages: 1496-1502

10.1093/cid/ciab761 | PMID 34731234 Get It

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with >2 million genomes sequenced at this writing. The rise of more transmissible variants of concern that affect vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution. Clinicians are also eager to take advantage of the information provided by SARS-CoV-2 genotyping beyond surveillance purposes. Here, we review the potential role of SARS-CoV-2 genotyping in clinical care. The review covers clinical use cases for SARS-CoV-2 genotyping, methods of SARS-CoV-2 genotyping, assay validation and regulatory requirements, clinical reporting for laboratories, and emerging issues in clinical SARS-CoV-2 sequencing. While clinical uses of SARS-CoV-2 genotyping are currently limited, rapid technological change along with a growing ability to interpret variants in real time foretell a growing role for SARS-CoV-2 genotyping in clinical care as continuing data emerge on vaccine and therapeutic efficacy.
Isotopic Distribution Calibration for Mass Spectrometry
Maus, Anthony , Kemp, Jennifer, Hoffmann, Todd J., Ramsay, Steven L., Grebe, Stefan K., Maus, Anthony D , Kemp, Jennifer V, Grebe, Stefan K G

Mayo Clinic

Analytical Chemistry | September 7, 2021 | Volume: 93 | Issue: 37 | Pages: 12532-12540

10.1021/acs.analchem.1c01672 | PMID 34490782 Get It

Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
Bergholtz, Helga , Carter, Jodi M. , Cesano, Alessandra, Cheang, Maggie C.U. , Church, S. , Divakar, Prajan , Fuhrman, Christopher A. , Goel, Shom , Gong, Jingjing , Guerriero, Jennifer L. , Hoang, Margaret L. , Hwang, E. Shelley , Kuasne, Hellen, Lee, Jinho , Liang, Yan , Perez, Jessica, Prat, Aleix , Pusztai, Lajos , Reeves, Jason , Riazalhosseini, Yasser , Richer, Jennifer K. , Şahin, Özgür , Sato, Hiromi , Sørlie, Thérese , Swarbrick, Alexander , Thompson, E. Aubrey , Tolaney, Sara M. , Warren, Sarah H. , Cheang, Maggie Chon U , Church, Sarah E , Prat, Aleix , Pusztai, Lajos , Sahin, Özgür , Sørlie, Therese , Liang, Yan , Carter, Jodi , Mittendorf, EA , Schlam, Ilana Miriam , Stover, Daniel G. , Swain, Sandra M. , Warren, Sarah

Mayo Clinic

Cancers | September 6, 2021 | Volume: 13 | Issue: 17 | Pages: 4456

10.3390/cancers13174456 | PMID 34503266 Get It

Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction of therapeutic response and prognostication. High-plex spatial profiling of tumors enables characterization of heterogeneity in the breast TME, which can holistically illuminate the biology of tumor growth, dissemination and, ultimately, response to therapy. The GeoMx Digital Spatial Profiler (DSP) enables researchers to spatially resolve and quantify proteins and RNA transcripts from tissue sections. The platform is compatible with both formalin-fixed paraffin-embedded and frozen tissues. RNA profiling was developed at the whole transcriptome level for human and mouse samples and protein profiling of 100-plex for human samples. Tissue can be optically segmented for analysis of regions of interest or cell populations to study biology-directed tissue characterization. The GeoMx Breast Cancer Consortium (GBCC) is composed of breast cancer researchers who are developing innovative approaches for spatial profiling to accelerate biomarker discovery. Here, the GBCC presents best practices for GeoMx profiling to promote the collection of high-quality data, optimization of data analysis and integration of datasets to advance collaboration and meta-analyses. Although the capabilities of the platform are presented in the context of breast cancer research, they can be generalized to a variety of other tumor types that are characterized by high heterogeneity.
Glioblastoma as an age-related neurological disorder in adults
Kim, Miri , Mozny, Andreas , Kocherginsky, Masha , O’Shea, Kaitlyn , Zhai, Lijie , Bollu, Lakshmi Reddy , Rabin, Erik E. , Dixit, Karan , Kumthekar, Priya , Platanias, Leonidas C. , Hou, Lifang , Wu, Jennifer D. , Hrachova, Maya , Merrill, Sarah , Mrugała, Maciej M. , Prabhu, Vikram C. , James, C. David , Ostrom, Quinn T. , Johnson, Margaret , Reardon, David A. , Lukas, Rimas V. , Kumthekar, Priya , Merrill, Sarah A , Wainwright, Derek A , Kim, Miri , Wu, Jennifer , Hou, Lifang , Ladomersky, Erik , Reinstein, Zachary Z. , Bell, April , Lauing, Kristen L. , Zheng, Yinan , Zhang, Bin , Horbinski, Craig , Yamini, Bakhtiar , Ostrom, Quinn T

Mayo Clinic

Neuro-Oncology Advances | September 4, 2021 | Volume: 3 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdab125 | PMID 34647022 Get It

Abstract Background Advanced age is a major risk factor for the development of many diseases including those affecting the central nervous system. Wild-type isocitrate dehydrogenase glioblastoma (IDHwt GBM) is the most common primary malignant brain cancer and accounts for ≥90% of all adult GBM diagnoses. Patients with IDHwt GBM have a median age of diagnosis at 68–70 years of age, and increasing age is associated with an increasingly worse prognosis for patients with this type of GBM. Methods The Surveillance, Epidemiology, and End Results, The Cancer Genome Atlas, and the Chinese Glioma Genome Atlas databases were analyzed for mortality indices. Meta-analysis of 80 clinical trials was evaluated for log hazard ratio for aging to tumor survivorship. Results Despite significant advances in the understanding of intratumoral genetic alterations, molecular characteristics of tumor microenvironments, and relationships between tumor molecular characteristics and the use of targeted therapeutics, life expectancy for older adults with GBM has yet to improve. Conclusions Based upon the results of our analysis, we propose that age-dependent factors that are yet to be fully elucidated, contribute to IDHwt GBM patient outcomes.
A multicenter analysis of the prognostic value of histone H3 K27M mutation in adult high-grade spinal glioma
Moniz‐Garcia, Diogo , Higgins, Dominique , Vivas-Buitrago, Tito , Jentoft, Mark E. , Solomon, David A. , Pennington, Zach , Sherman, Wendy, Delgardo, Mychael, Bydon, Mohamad , Kalani, Maziyar A. , Zanazzi, George , Tsankova, Nadejda M. , McCormick, Paul C., Sciubba, Daniel M. , Lo, Sheng-Fu Larry , Clarke, Jennifer , Quiñones‐Hinojosa, Alfredo , Garcia, Diogo P, Jentoft, Mark, Solomon, David A , Pennington, Zach , Garcia, Diogo Moniz , Tsankova, Nadejda M , Akinduro, Oluwaseun O. , Daniels, David J. , Bendok, Bernard R. , Abode-Iyamah, Kingsley

Mayo Clinic

Journal of Neurosurgery: Spine | September 3, 2021 | Volume: 35 | Issue: 6 | Pages: 834-843

10.3171/2021.2.spine201675 | PMID 34416733 Get It

OBJECTIVE High-grade spinal glioma (HGSG) is a rare but aggressive tumor that occurs in both adults and children. Histone H3 K27M mutation correlates with poor prognosis in children with diffuse midline glioma. However, the role of H3 K27M mutation in the prognosis of adults with HGSG remains unclear owing to the rarity of this mutation, conflicting reports, and the absence of multicenter studies on this topic. METHODS The authors studied a cohort of 30 adult patients with diffuse HGSG who underwent histological confirmation of diagnosis, surgical intervention, and treatment between January 2000 and July 2020 at six tertiary academic centers. The primary outcome was the effect of H3 K27M mutation status on progression-free survival (PFS) and overall survival (OS). RESULTS Thirty patients (18 males and 12 females) with a median (range) age of 50.5 (19–76) years were included in the analysis. Eighteen patients had H3 K27M mutation–positive tumors, and 12 had H3 K27M mutation–negative tumors. The median (interquartile range) PFS was 3 (10) months, and the median (interquartile range) OS was 9 (23) months. The factors associated with increased survival were treatment with concurrent chemotherapy/radiation (p = 0.006 for PFS, and p ≤ 0.001 for OS) and American Spinal Injury Association grade C or better at presentation (p = 0.043 for PFS, and p < 0.001 for OS). There were no significant differences in outcomes based on tumor location, extent of resection, sex, or H3 K27M mutation status. Analysis restricted to HGSG containing necrosis and/or microvascular proliferation (WHO grade IV histological features) revealed increased OS for patients with H3 K27M mutation–positive tumors (p = 0.017). CONCLUSIONS Although H3 K27M mutant–positive HGSG was associated with poor outcomes in adult patients, the outcomes of patients with H3 K27M mutant–positive HGSG were somewhat more favorable compared with those of their H3 K27M mutant–negative HGSG counterparts. Further preclinical animal studies and larger clinical studies are needed to further understand the age-dependent effects of H3 K27M mutation.
Longitudinal scoliosis behavior in Chiari malformation with and without syringomyelia
Chotai, Silky , Nadel, Jeffrey , Holste, Katherine G. , Mossner, James M. , Smith, Brandon W. , Kapurch, Joseph, Muraszko, Karin M. , Garton, Hugh , Maher, Cormac O. , Strahle, Jennifer M. , Kapurch, Joseph R

Mayo Clinic

Journal of Neurosurgery: Pediatrics | September 3, 2021 | Volume: 28 | Issue: 5 | Pages: 585-591

10.3171/2021.5.peds20915 | PMID 34479199 Get It

OBJECTIVE The objective of this study was to understand the natural history of scoliosis in patients with Chiari malformation type I (CM-I) with and without syringomyelia. METHODS A retrospective review of data was conducted. Patients with CM-I were identified from a cohort of 14,118 individuals age 18 years or younger who had undergone MRI over an 11-year period at the University of Michigan. Patients eligible for study inclusion had a coronal curve ≥ 10° on radiography, associated CM-I with or without syringomyelia, and at least 1 year of clinical follow-up prior to any surgery. Curve magnitude at initial diagnosis, prior to posterior fossa decompression (PFD; if applicable), and at the last follow-up (prior to any surgical correction of scoliosis) was recorded, and clinical and radiographic characteristics were noted. The change in curve magnitude by 10° was defined as curve progression (increase by 10°) or regression (decrease by 10°). RESULTS Forty-three patients met the study inclusion criteria and were analyzed. About one-third (35%) of the patients presented with symptoms attributed to their CM-I. The mean degree of scoliosis at presentation was 32.6° ± 17.7°. Twenty-one patients (49%) had an associated syrinx. The mean tonsil position below the level of the foramen magnum was 9.8 ± 5.8 mm. Patients with a syrinx were more likely to have a curve > 20° (86% vs 41%, p = 0.002). Curve magnitude remained stable (≤ ±10°) in 77% of patients (33/43), progressed in 16% (7/43), and regressed in 7% (3/43). Mean age was higher (14.8 ± 0.59 years) among patients with regressed curves (p = 0.026). All regressed curves initially measured ≤ 20° (mean 14° ± 5.3°), and none of the patients with regressed curves had a syrinx. The change in curve magnitude was statistically similar in patients with (7.32° ± 17.7°) and without (5.32° ± 15.8°) a syrinx (p = 0.67). After a mean follow-up of 3.13 ± 2.04 years prior to surgery, 27 patients (63%) ultimately underwent posterior fossa or scoliosis correction surgery. For those who eventually underwent PFD only, the rate of change in curve magnitude prior to surgery was 0.054° ± 0.79°. The rate of change in curve magnitude was statistically similar before (0.054° ± 0.79°) and after (0.042° ± 0.33°) surgery (p = 0.45) for patients who underwent PFD surgery only. CONCLUSIONS The natural history of scoliosis in the presence of CM-I is variable, though most curves remained stable. All curves that regressed were ≤ 20° at initial diagnosis, and most patients in such cases were older at scoliosis diagnosis. Patients who underwent no surgery or PFD only had similar profiles for the change in curve magnitude, which remained relatively stable overall, as compared to patients who underwent PFD and subsequent fusion, who demonstrated curve progression. Among the patients with a syrinx, no curves regressed, most remained stable, and some progressed. Understanding this variability is a first step toward building a prediction model for outcomes for these patients.